Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | TK2 | O00142 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274511 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4274515 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15740173 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL10015654 | 0.91 | TK1 (0.61) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4264413 | 0.91 | TK1 (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL12047413 | 0.91 | TK1 (0.65) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2611657 | 0.91 | TK1 (0.65) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7268275 | 0.91 | LMNA (0.67) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL5532799 | 0.91 | TK1 (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL1007186 | 0.91 | TK1 (0.65) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | TK1 92/4885LMNA 4722/4885SMN1; SMN2 2967/4885 |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | TK1 891/4885LMNA 4451/4885SMN1; SMN2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.